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Abstract Scorpion venom contains toxins that act on ion 
channels. Some are responsible for the noxious effects observed 
when people are stung by scorpions. The study of the 
neutralization of these molecules and the production of mono-
clonal antibodies (mAbs) should prove valuable. Toxin II from 
Androctonus australis hector scorpion (Aahll) is one of the most 
potent toxins and has been well-characterized and studied. 
Producing mAbs against such molecules is often difficult due to 
their toxicity. We used a synthetic, non-toxic analog, (Abu)8-
Aahll, to obtain mAbs which recognize and neutralize the native 
toxin Aahll. Sets of peptides spanning the entire sequence of 
Aahll were assayed to identify the binding sites of the mAbs. The 
various mAbs recognized only the largest peptides (12-17 
residues). They recognized peptides corresponding to different 
parts of the Aahll sequence, suggesting that several regions of 
the (Abu)s-Aahll sequence mimic Aahll epitopes and then elicit 
mAbs directed against toxin. 
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1. Introduction 
Hybridoma technology [1] is widely used in clinical appli-
cations (diagnosis and therapy; [2,3]) and topographical anal-
ysis of antigens [4,5]. It can be useful to investigate the struc-
ture-activity relationships and the specificity of the 
neutralization of the lethal effect of infectious or toxic mole-
cules. Numerous animal species cause mammal ian envenoma-
tion. This phenomenon is mainly due to venom proteins 
which disturb vital functions. Producing monoclonal antibod-
ies (mAbs) against these proteins may prove valuable, but the 
toxicity of the immunogen sometimes renders their production 
very difficult. This is the case for scorpion toxins, for which 
only a few mAbs have been reported [6,7]. Low-dose immu-
nization or modification of the immunogen was necessary to 
obtain live immunized animals. The venom of the scorpion 
Androctonus australis hector contains several toxins that act 
on ion channels. The most potent, Aah l l , interacts with po-
tential-dependent sodium channels and can kill mice (LD 5 0 in 
BALB/c of 300 ng/20 g mice when injected subcutaneously). 
We protected mice against challenge by native toxin or venom 
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using a non-toxic analog of Aah l l , the (Abu)8-AahII , encom-
passing the entire sequence of the native toxin but without 
disulphide bridges [8]. 
In the present work, (Abu)g-Aahll was used as a non-toxic 
immunogen to generate mAbs. The mAbs obtained were an-
alysed for their capacity to recognize and neutralize the native 
toxin. Delineation of antibody binding sites was performed 
using different sets of synthetic peptides. 
2. Materials and methods 
2.1. Peptide synthesis 
Chemical synthesis and characterization of the immunogen, (Abu)8-
Aahll, was as previously described [8]. Two series of overlapping 
peptides (12 to 17 residues) were tested for recognition by mAbs using 
ELISA. In one series, cysteine residues were blocked by acetamido-
methyl group (Acm) and in the other cysteine residues were replaced 
by a-aminobutyric acid (Abu). Sequences of Acm-containing peptides 
were: 1 (residues 1-15), 2 (6-22), 3 (13-27), 4 (18-32), 5 (23-37), 
6 (29^13), 7 (34-48), 8 (39-53), 9 (45-59) and 10 (49-64) and those 
of Abu-containing peptides were: 1 (1-13), 2 (8-19), 3 (15-27), 4 (23-
34), 5 (30-43), 6 (38-50), 7 (45-57) and 8 (52-64). Details of synthesis 
will be published elsewhere (Mabrouk et al., in preparation). The 58 
overlapping heptapeptides covering the entire 64-residue sequence of 
AaH II [9] were simultaneously synthesized by the Pepscan method 
[10], as described [11]. 
2.2. Immunization of mice 
Six-week-old females BALB/c were injected intraperitoneally (i.p.) 
and subcutaneously (s.c.) with 36 ug of (Abujg-Aahll in complete 
Freund adjuvant (CFA). Boosts of 20 u.g in incomplete adjuvant 
(IFA) were given on days 24, 42, 66, 86 and 130. Sera from all 
bleedings were tested against Aahll using ELISA. The sera were 
tested in a liquid-phase assay (RIA) and the mouse with the highest 
response was selected for fusion. Three boosts of 50, 75 and 75 u,g of 
(Abu)g-Aahll in 0.9% NaCl were given at 1 h intervals (i.p., i.p. and 
intravenously (i.v.), respectively) three days before fusion. 
2.3. Generation of mAbs 
mAbs were produced as described by Galfre and Milstein [12]. 
Splenocytes from immune mouse (74 X106 cells) were fused with 
X63-F cells (15X106) using 50% of polyethyleneglycol 1500 (Boeh-
ringer). Hybrids were selected in HAT-RPMI 1640 medium (Eurobio) 
containing 15% FCS (Boehringer). Antibody-secreting cells were ex-
panded and cloned twice at limiting dilution using mouse peritoneal 
macrophages as feeder cells. Cloned cells were grown as ascites tu-
mors in pristane-primed mice. 
Antibodies were purified on protein-A Sepharose (Pharmacia) as 
described by Devaux et al. [13] using 0.1 M Na citrate pH 5 as the 
elution buffer. They were then dialysed in TBS. Purity was assessed 
using 12% SDS-PAGE and p / 3-9 IEF gel (Phast System, Pharmacia). 
The protein concentration of IgG solutions was measured by UV 
spectrophotometry using ^278 = 1-4 cm
2/mg. Antigen-mediated ELISA 
was used to determine the heavy chain isotype (Sigma ISO-2 kit) or 
the light chain isotype (rat mAbs anti-mouse kappa or lambda chain 
from Sigma). 
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2.4. Immunoassays 
2.4.1. RIA. The binding of each mAb to 125I-AahII was assessed. 
125I-AahII was prepared and purified as previously described [14]. 
Thirty microlitres of each dilution of different concentrations of pu-
rified IgG were mixed with 30 ill of 125I-AahII (5 X 10"10 M) and 30 ul 
of PBS-0.1% BSA. The mixtures were incubated for 90 min at 37°C 
and then overnight at 4°C. Sheep anti-mouse precipitating antibody 
(0.5 ml; UCB Bioproducts, Belgium) was added. The mixtures were 
incubated for 30 min at 4°C, then centrifuged at 9000 Xg for 10 min. 
Radioactivity was measured with a gamma counter (Packard Crystal 
II). All assays were duplicated. 
2.4.2. ELISA. Microtiter plates (Maxisorb, NUNC) were coated 
with 100 ul/well of Aahll (1 ug/ml) in PBS overnight at 4°C. Blocking 
solution (150 ul of 5% non-fat milk in PBS) was added to each well 
and the samples incubated for 1 h at 37°C. The plates were then 
washed with 0.9% NaCl containing 0.05% Tween 20 (NT). Cell super-
natants or IgG were added (100 ul/well) for 90 min at 37°C. The 
plates were washed with NT and further incubated with 100 ul/well 
of a 1:1000 dilution of peroxidase-conjugated goat anti-mouse IgG 
(Jackson, France). The wells were washed again with NT. Peroxidase 
substrate solution (TMB, Kirkegaard and Perry Labs, MD) was 
added (100 ul/well) and the plates were left 10 min at room temper-
ature. Absorbance at 620 nm was measured using a Titertek Multi-
skan photometer (Flow Labs). The assays were duplicated. 
For epitope mapping, ELISAs were carried out as described above. 
The plates were coated with peptides at a concentration of 2 ug/ml 
and purified IgG were diluted to between 0.03 and 1 nmol/ml. The 
mean of three independent experiments is given. Dissociation con-
stants (KD) of toxin-antibody interactions were determined under 
the conditions described by Friguet et al. [15] using ELISA to measure 
the concentration of free antibody at equilibrium. 
2.5. Neutralization assays 
Receptor binding assay. Rat brain synaptosomal fraction was pre-
pared using the method of Gray and Whittaker [16] described by 
Jover et al. [17]. Binding assays were performed in 140 mM choline 
chloride, 5.4 mM KC1, 0.8 mM MgCl2, 1.8 mM CaCl2, 25 mM 
HEPES and 0.1% BSA at pH 7.4. Thirty microlitres of 12BI-AahII 
(5 X 10-10M) were incubated with 30 ul of each of a series of dilutions 
of purified IgG for 90 min at 37°C. Synaptosomal preparation was 
added (30 ill) and the incubation was continued for an additional 
30 min at 37°C. The mixtures were centrifuged at 9000Xg and washed 
three times. The radioactivity of the pellets was measured. Assays 
were duplicated. 
2.5.1. Assays in vivo 
The neutralizing capacity of mAbs was tested by the intracerebro-
ventricular (i.c.v.) route. Each of a series of amounts of Aahll equal 
or higher than the value of the lethal dose (LD50 = 1.5 ng for C57BL/6 
mice) were preincubated for 90 min at 37°C and 30 min at 4°C with 
un equal volume of protein-A Sepharose purified IgG from mAbs or 
from nonimmune serum. Female C57BL/6 mice (groups of six) were 
injected by the i.c.v. route. Surviving mice were recorded after 24 h. 
3. Results 
3.1. Production of hybridomas and monoclonal antibodies 
(mAbs) 
Immunization of BALB/c mice with (Abu)s -Aahll is a non-
toxic alternative to low-dose immunization with native toxin. 
(Abu)8-Aahll was injected into several mice and the mouse 
with the strongest response was selected by the ability of its 
antibodies to recognize AaH II on coated plates (ELISA) or 
125I-labelled Aahll (RIA) (Fig. 1). Serum titers determined by 
ELISA were 1/50000 with (Abu)8-AahII and 1/5000 with Aa-
hll-coated plates. Hybrid cells grew in more than 50% of the 
wells (800) containing cell fusion mixture. Nine supernatants 
cross-reacted with Aahll-coated plates. Cells from these wells 
were cloned twice. Three clones (denoted 23C6, 37D3, 26D8) 
developed suitably and were grown in mice. MAbs were pu-
rified from ascitic fluids by protein A-Sepharose chromatog-
raphy. They all belong to the IgGl subclass and their light 
chain is of kappa type. 
3.2. General characteristics of mAbs 
Purified mAbs were resolved as a single band in non-reduc-
ing 12% SDS-PAGE and in pi 5-9 IEF gel (data not shown). 
They had different pis (Table 1). All mAbs recognized Aahll 
in indirect ELISA, with titers between 5 and 100 nM IgG. The 
affinity of 23C6 and 37D3 mAbs for the native Aahll toxin 
was measured by competitive ELISA at equilibrium. KQ val-
ues were 0.4 and 4 u\M, respectively (Table 1). 
3.3. Neutralizing effect of mAbs on the Aahll binding on rat 
synaptosomes and on Aahll toxicity in mice 
The lethal effect of the scorpion venom is mainly due to the 
binding of Aahll to voltage-dependent sodium channels. The 
capacity of mAbs to inhibit the biological effects of Aahll was 
tested both in vitro and in vivo. The inhibition of the binding 
of 125I-AahII to its site on rat brain synaptosomes was tested. 
All mAbs showed dose-dependent inhibition (Fig. 2). The 
efficiency of the inhibition was paralleled to the measured 
KB of mAbs for the native toxin and clearly higher than the 
non-specific effect obtained with IgG from preimmune serum 
(Fig. 2). IC50 values (concentration of IgG giving half-binding 
inhibition of Aahll) were 1 (23C6), 5 (37D3) and 8 uM 
(26D8). 
The toxicity of Aahll was measured in C57BL/6 mice by 
i.c.v. injection. The protective effect of mAbs was evaluated 
by preincubating each of a series of amounts of Aahll with 
purified IgG from each mAb and injecting the mixture by the 
i.c.v. route to mice (six per Aahll concentration). The controls 
were performed in the same way, mAb being replaced by IgG 
from mouse nonimmune serum at the same concentration 
(2.5 mg/ml). In the presence of mAb 23C6, 50% of the mice 
injected survived the injection of 2 LD50 whereas all the con-
trol mice died. The protective capacity of 23C6 mAb was 
about 200 LD50 by mg of purified IgG from ascitic fluid. 
No significant protection was observed with the other mAbs. 
Table 1 
Characteristics of anti-(Abu)8-AahII mAbs 
mAbs 
23C6 
37D3 
26D8 
Isotype 
IgGl,K 
IgGl,K 
IgGl,K 
P/ 
6.3 
7.6 
5.8 
Titer (ELISA)" XI0" 9 
(Abu)8-AahII 
0.09 
0.10 
5.00 
Aahll 
5 
19 
97 
KB (ELISA)b 
Aahll 
4 
39 
d 
X10"7 Kv (RIA)
CX10 -7 
Aahll 
3.7 
d 
d 
aTiter was the concentration of IgG giving half-binding to (Abu)8-AahII or Aahll-coated plates. 
hKD from competitive ELISA were measured as described in Friguet et al. [15]. 
cKo from competitive RIA was calculated as in Bahraoui et al. [6]. 
dNo competition was observed at the highest concentration tested (5 X 10~6). 
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Fig. 1. Reactivity of polyclonal anti-(Abu)8-AahII serum with Aahll 
toxin. BALB/c mice were immunized with (Abu)8-AahII. Serial dilu-
tions of immune sera were tested on 1 ug/ml Aahll-coated plates in 
ELISA (A) or against 126I-AahII in RIA (B). 
3.4. Epitope mapping of mAbs using different sets of 
Aah II-derived synthetic peptides 
Two different sets of overlapping linear peptides were used 
for epitope mapping. They were 12-17 residues long. The 
cysteine residues were replaced by acetamidomethyl groups 
(Acm) in one set, and by a-aminobutyric acid (Abu) in the 
other. The mAbs 23C6 and 26D8 reacted strongly with pep-
tides from the C-terminal part of the molecule (Fig. 3). MAb 
23C6 recognized the C-terminal Acm (residues 49-64) or Abu 
(residues 52-64) peptides. MAb 26D8 recognized two Acm 
peptides (residues 45-59 and 49-64) and one Abu-peptide 
(residues 45-57). In order to confirm that the two sequences 
recognized by mAbs 23C6 and 26D8 were differents, an an-
other synthetic peptide (sequence 50-59 [18]) was tested. It 
was not recognized by mAb 23C6 but gave a strong signal 
with mAb 26D8 (data not shown). MAb 37D3 reacted with 
Acm-peptides 6-22 and 23-37 but not with Abu-peptides. In 
addition, no mAbs (even at high IgG concentration) reacted 
with heptapeptides synthesized in the Pepscan format [11,19]. 
4. Discussion and conclusion 
There are several possible strategies for eliciting mAbs ac-
tive against highly toxic molecules. Low doses, chemical de-
toxification and synthetic peptides have been used. We have 
previously obtained a neutralizing mAb of high affinity using 
low-dose of native Aahll [6]. Here, we tried to obtain addi-
tional mAbs by using a non-toxic immunogen, (Abu)g-Aahll. 
Our choice was validated by the successful mice protection 
experiments [8] using this analog which contains the entire 
sequence of Aahll. In contrast, previous trials using short 
immunogenic peptides (residues 50-59 and 1-8), produced 
toxin-specific antibodies, but failed to protect mice against 
native toxin irrespective of how the immunogen was for-
mulated ([20] and Chavez-Olortegui and Granier, unpub-
lished). We obtained several mAbs by screening clones pro-
duced by cell fusion for reaction to the native toxin. They 
recognized Aahll both in solid- (ELISA) or liquid-phase 
(RIA) assays but with lower affinity than that of mAb 4C1. 
The strongest reaction was obtained with mAb 23C6 which 
inhibited the binding of 125I-AahII to rat brain synaptosomes 
(IC50 = 1 uM). The mAbs 37D3 and 26D8 also had a slight 
inhibitory effect (IC50 = 5 uM and 8 |iM, respectively). In 
addition, preincubation of Aahll toxin with 23C6 IgG caused 
a doubling of the LD50 in C57BL/6 mice. 
We identified the antigenic sites of mAbs on toxin II using 
synthetic peptides from Aahll sequence in ELISA. The mAbs 
23C6 and 26D8 recognized the C-terminal part of Aahll. 
Their sites overlapped extending from residues 49 to 64 and 
45 to 64, respectively. The combination of the results obtained 
in ELISA with the two sets of overlapping peptides (acm- and 
abu-peptides) allowed to define minimal sequences recognized 
by mAbs as residues 52-64 (mAb 23C6) and 49-57 (mAb 
26D8). The mAb 37D3 is unusual as it binds two non-over-
lapping Acm-peptides (residues 6-22 and 23-37) separated by 
two unreactive peptides, but does not recognize smaller se-
quences (Abu-peptides 8-19 and 23-34). All three mAbs failed 
to bind to smaller peptides (heptapeptides in the Pepscan for-
mat). 
These antibodies, produced against a 64-residue synthetic 
analog devoid of disulphide bridges were selected on the basis 
of their cross-reaction with the intact toxin. They recognize 
peptides of 12-17 residues. This does not necessarily mean 
that all these residues are involved in the interaction between 
paratope and epitope. This size may be critical to mimic epit-
opes with a local secondary structure very similar to that 
found in the intact Aahll toxin. Some residues, although 
not directly involved, may play a role in stabilizing the inter-
action and/or the relevant structure. All identified mAb sites 
contain sequences forming (3-turns in the Aahll X-ray model 
[21]: the fourth (3-turn (residues 52-55) for both mAbs 26D8 
and 23C6, first (residues 8-12) and second (residues 27-30) 
P-turns for mAb 37D3. In addition the defined mAb-binding 
sequences are the most accessible sites on the molecule [22,23]. 
The strong antigenicity of the C-terminus part of Aahll was 
previously demonstrated using rabbit sera specific for toxins 
and synthetic peptides derived from the sequence of Aahll 
[23] or obtained by the Pepscan method [11]. Polyclonal anti-
100 
O 
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m 
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Log [IgG], M 
Fig. 2. Aahll neutralizing capacity of anti-(Abu)8-Aahll mAbs. 
Binding of 125I-AahII (10~10 M) to rat brain synaptosomes was in-
hibited by preincubation with various dilutions of the IgG mAbs. 
BALB/c preimmune serum was used as a control (NI). B and Bo 
was the binding measured in presence (B) or in absence (Bo) of 
IgG. 
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Fig. 3. Epitope analysis of mAbs. Antibodies were tested for binding to different synthetic peptides derived from the Aahll sequence. (A) Bind-
ing pattern of mAbs to Acm-peptides or (B) binding pattern of mAbs to Abu-peptides as determined by ELISA. (C) Location of the binding 
sites of the mAbs on the Aahll sequence as deduced from the ELISA data. 
bodies could be induced by BSA-coupled peptide (50-59) in 
rabbits. They neutralized the lethal effect of the toxin [18] but 
we failed to obtain neutralizing antibodies in mice whatever 
was the presentation of the peptide [20]. Furthermore, the 
immunoreactivity of the neutralizing mAb 4C1 obtained by 
immunization with Aahll was strongly altered when K58 or 
H54/64 were modified [6]. The binding site of mAb 23C6 on 
Aahll was a sequence containing the highly reactive K58 
whose chemical modification abolishes binding of the toxin 
to its pharmacological site on Na+-channel ([24] and Hassani 
et al. unpublished). The three mAbs induced by (Abu)8-AahII 
were able to inhibit the binding of Aahll to its receptor. It is 
unknown if this inhibition is due to steric hindrance of the 
pharmacological site or to direct interaction with this site. 
Complete description of antigen-antibody interaction involves 
both structural and functional analyses [25-27]. Functional 
immunoassays using synthetic peptides to define antigenic de-
terminants on proteins have often been successfully used 
[28,29]. Our results with mAbs 23C6 and 26B8, together 
with previous work, suggest that there is a dominant antigenic 
domain on the Aahll toxin. It consists of several overlapping 
functional epitopes. 
This study shows that mAbs may be obtained using (Abu)g-
Aahll as the immunogen. The diversity of these mAbs and the 
location of their binding sites may explain the strong protec-
tion of (Abu)8-AahII-immunized mice against challenge by 
natural toxin [8]. If the entire accessible surface of a protein 
is a continuum of overlapping epitopes [30,31], a full-length 
analog may be more valuable than some carrier-coupled pep-
tides as a non-toxic immunogen. 
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